Jean-Christophe Tellier'un ücretlendirmesi UCB'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Dec 31 2024	€7m	€1m	€1b
Sep 30 2024	n/a	n/a	€653m
Jun 30 2024	n/a	n/a	€240m
Mar 31 2024	n/a	n/a	€292m
Dec 31 2023	€7m	€1m	€343m
Jun 30 2023	n/a	n/a	€332m
Mar 31 2023	n/a	n/a	€376m
Dec 31 2022	€6m	€1m	€420m
Jun 30 2022	n/a	n/a	€887m
Mar 31 2022	n/a	n/a	€971m
Dec 31 2021	€6m	€1m	€1b
Sep 30 2021	n/a	n/a	€996m
Jun 30 2021	n/a	n/a	€936m
Mar 31 2021	n/a	n/a	€834m
Dec 31 2020	€7m	€1m	€732m
Jun 30 2020	n/a	n/a	€743m
Mar 31 2020	n/a	n/a	€767m
Dec 31 2019	€87k	n/a	€790m

Tazminat ve Piyasa: Jean-Christophe 'nin toplam tazminatı ($USD 7.72M ), Belgian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 3.02M ).

Tazminat ve Kazançlar: Jean-Christophe 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Jean-Christophe Tellier (65 yo)

10.3yrs

Görev süresi

€6,793,643

Tazminat

Dr. Jean-Christophe Tellier serves as Executive Vice President and President of European Operations at Ucb S.A. Dr. Tellier served as President and General manager of North American operations at Ipsen S.A...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jean-Christophe Tellier	CEO & Executive Director	10.3yrs	€6.79m	Veri yok
Sandrine Dufour	Executive VP	4.8yrs	Veri yok	Veri yok
Denelle J. Johnson	Executive VP & General Counsel	2.1yrs	Veri yok	Veri yok
Jean-Luc Fleurial	Executive VP & Chief Human Resources Officer	5.3yrs	Veri yok	Veri yok
Emmanuel Caeymaex	Executive VP & Chief Commercial Officer	10.3yrs	Veri yok	Veri yok
Kirsten Lund-Jurgensen	Executive Vice President of Patient Supply	1.3yrs	Veri yok	Veri yok
Fiona du Monceau	Executive Vice President of Patient Evidence	1.1yrs	€32.84k	Veri yok
Caroline Vancoillie	Chief Accounting Officer	12.2yrs	Veri yok	Veri yok
Alistair Henry	Executive VP & Chief Scientific Officer	1yr	Veri yok	Veri yok
Antje Witte	Head of Investor Relations	15.3yrs	Veri yok	Veri yok
Gwendoline Ornigg	Head of Global Communication	no data	Veri yok	Veri yok
Veronique Toully	Head of Sustainability	no data	Veri yok	Veri yok

5.0yrs

Ortalama Görev Süresi

57.5yo

Ortalama Yaş

Deneyimli Yönetim: UCB 'un yönetim ekibi deneyimli ve deneyimlidir ( 5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jean-Christophe Tellier	CEO & Executive Director	11.1yrs	€6.79m	Veri yok
Gerhard Mayr	Honorary Chairman	no data	€70.00k	Veri yok
Mark Eyskens	Honorary Chairman	20.3yrs	€15.50k	Veri yok
Daniel Janssen	Honorary Deputy Chairman	no data	€28.50k	Veri yok
Georges Jacobs Hagen	Honorary Chairman	no data	€30.00k	Veri yok
Diégo du de Bergendal	Honorary Chairman	4.1yrs	€87.50k	Veri yok
Karel Boone	Honorary Chairman	no data	€49.00k	Veri yok
Dame Davies	Independent Director	11.1yrs	€141.39k	Veri yok
Jonathan Peacock	Independent Chair of the Board	4.1yrs	€390.00k	Veri yok
Charles-Antoine Emmanuel Janssen	Vice-Chair of the Board	13.1yrs	€138.53k	Veri yok
Jonkheer van Rijckevorsel	Director	11.1yrs	€103.95k	Veri yok
Rodolfo Savitzky	Independent Director	1.3yrs	€87.33k	Veri yok

11.1yrs

Ortalama Görev Süresi

73yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: UCB 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 11.1 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/05/25 00:13
Gün Sonu Hisse Fiyatı	2025/05/23 00:00
Kazançlar	2024/12/31
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

UCB SA 51 Bu analistlerden 16, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Mark van der Geest	ABN AMRO Bank N.V.
Kamla Singh	AlphaValue
Brian Bourdot	Barclays

UCB Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Why We Think UCB SA's (EBR:UCB) CEO Compensation Is Not Excessive At All

UCB SA Announces Step Down of Fiona Du Monceau from the Board of Directors

UCB SA, Annual General Meeting, Apr 24, 2025

Insufficient new directors

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

UCB SA, Annual General Meeting, Apr 27, 2023

Recent updates

UCB SA to Report First Half, 2025 Results on Jul 31, 2025

Dividend of €0.97 announced

Why We Think UCB SA's (EBR:UCB) CEO Compensation Is Not Excessive At All

UCB SA's (EBR:UCB) Share Price Is Still Matching Investor Opinion Despite 25% Slump

Investor sentiment deteriorates as stock falls 20%

New minor risk - Share price stability

UCB Presents Latest Research Across Leading Neurology Portfolio At American Academy of Neurology (AAN) Meeting

We Think UCB (EBR:UCB) Can Manage Its Debt With Ease

UCB SA Announces Step Down of Fiona Du Monceau from the Board of Directors

UCB Announces Positive Data from Studies Inviding Its Investigational Therapy, Doxecitine and Doxribtimine

Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of Fintepla (Fenfluramine) in Children and Adults with Dravet Syndrome

Consensus EPS estimates increase by 13%

UCB's (EBR:UCB) Earnings Are Of Questionable Quality

BIMZELX's Successful Launch Will Expand Future Market Opportunities In Dermatology And Rheumatology

UCB SA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

UCB SA (EBR:UCB) Not Lagging Market On Growth Or Pricing

Full year 2024 earnings: EPS and revenues exceed analyst expectations

UCB SA Proposes Dividend

UCB’s Bimzelx (bimekizumab) Poised to Disrupt the U.S. Psoriatic Arthritis Market

Is UCB (EBR:UCB) A Risky Investment?

Consensus EPS estimates increase by 18%

UCB SA Receives U.S. FDA Approval for Bimzelx (Bimekizumab-Bkzx) as the First Il-17A and Il-17F Inhibitor for Adults with Moderate-Severe Hidradenitis Suppurativa

Ucb Announces New Bimzelx (Bimekizumab-Bkzx) Data at Acr Convergence 2024

Why We're Not Concerned About UCB SA's (EBR:UCB) Share Price

UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Consensus EPS estimates increase by 14%

Price target increased by 8.5% to €153

Analysts Have Made A Financial Statement On UCB SA's (EBR:UCB) Half-Yearly Report

First half 2024 earnings released: EPS: €1.10 (vs €1.64 in 1H 2023)

Investors Still Waiting For A Pull Back In UCB SA (EBR:UCB)

Price target increased by 7.2% to €135

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

Insufficient new directors

UCB SA to Report First Half, 2024 Results on Jul 25, 2024

Dividend of €0.95 announced

Consensus EPS estimates increase by 18%

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

Price target increased by 9.4% to €111

Consensus EPS estimates fall by 14%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

First half 2023 earnings released: EPS: €1.64 (vs €2.10 in 1H 2022)

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

Upcoming dividend of €0.93 per share at 1.5% yield

Consensus EPS estimates fall by 17%

Consensus EPS estimates fall by 16%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

First half 2022 earnings released

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated